Bile Acids as Hormones: The FXR-FGF15/19 Pathway

Cited by (422)

Items 101–200 of 422

1. Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy
   Marco A. Arrese, Vı́ctor Cortés, Francisco Barrera M., Flavio O. Nervi · 2017 · Current Opinion in Gastroenterology
2. Hepatic cholesterol accumulation ascribed to the activation of ileum Fxr-Fgf15 pathway inhibiting hepatic Cyp7a1 in high-fat diet-induced obesity rats
   Yingting Duan, Fan Zhang, Wenzhen Yuan, Yuhui Wei, Mengmeng Wei, Yan Zhou, Yuquan Yang, Yae Chang, Xinan Wu · 2019 · Life Sciences
3. Nutrition and Gastrointestinal Microbiota, Microbial-Derived Secondary Bile Acids, and Cardiovascular Disease
   José Rodríguez-Morató, Nirupa Rachel Matthan · 2020 · Current Atherosclerosis Reports
4. New Insights into Bile Acids Related Signaling Pathways in the Onset of Colorectal Cancer
   Cristiana Caliceti, Angela Punzo, Alessia Silla, Patrizia Simoni, Giulia Roda, Silvana Hrelia · 2022 · Nutrients
5. Postnatal Deletion of Fat Storage-inducing Transmembrane Protein 2 (FIT2/FITM2) Causes Lethal Enteropathy
   Vera J. Goh, Jolene S.Y. Tan, Bryan C. Tan, Colin J.P. Seow, Wei-Yi Ong, Yen Ching Lim, Lei Sun, Sujoy Ghosh, David L. Silver · 2015 · Journal of Biological Chemistry
6. Enterohepatic circulation of bile acids and their emerging roles on glucolipid metabolism
   Mengjun Chen, Chen Liu, Yue Wan, Lei Yang, Shu Jiang, Dawei Qian, Jin‐Ao Duan · 2020 · Steroids
7. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction
   Tilman Sauerbruch, Martin Hennenberg, Jonel Trebicka, Ulrich H. Beuers · 2021 · Frontiers in Physiology
8. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial
   Xiaotao Zhang, Ehsan Irajizad, Kristi Louise Hoffman, Johannes Francois Fahrmann, Fangyu Li, Yongwoo David Seo, Gladys J. Browman, Jennifer B. Dennison, Jody V. Vykoukal, Pamela N. Luna et al. · 2023 · EBioMedicine
9. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho
   Ting Fu, Young‐Chae Kim, Sangwon Byun, Dong-Hyun Kim, Sunmi Seok, Kelly M. Suino-Powell, H. Eric Xu, BYRON W. KEMPER, Jongsook Kim Kemper · 2015 · Molecular Endocrinology
10. Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications
    Gloria Álvarez‐Sola, Iker Uriarte, Maria Ujue Latasa, Maddalen Jiménez, Marina Bárcena‐Varela, Eva Santamaría, Raquel Urtasun, Carlos M. Rodríguez‐Ortigosa, Jesús Prìeto, Pedro Berraondo et al. · 2017 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
11. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
    Anca Daniela Petrescu, Sharon DeMorrow · 2021 · Cells
12. Zonation in NASH – A key paradigm for understanding pathophysiology and clinical outcomes
    Steinman, Jonathan B., Salomao, Marcela A., Pajvani, Utpal B. · 2021 · Liver International
13. Ceramide signaling in the gut
    Ying Li, Rebekah J. Nicholson, Scott A. Summers · 2022 · Molecular and Cellular Endocrinology
14. Connecting the Gut Microbiota and Neurodegenerative Diseases: the Role of Bile Acids
    Shixu Wang, Chongchong Xu, Hongyan Liu, Wei Wei, Xuemei Zhou, Haipeng Qian, Li Zhou, Haiqing Zhang, Li Ming Wu, Zhu Chen et al. · 2023 · Molecular Neurobiology
15. The role of bile acids in regulating glucose and lipid metabolism
    Hengcai Yu, Ruifang Nie, Chengwu Shen · 2023 · Endocrine Journal
16. Lactobacillus plantarum LP33 attenuates Pb-induced hepatic injury in rats by reducing oxidative stress and inflammation and promoting Pb excretion
    Ting Hu, Jiajia Song, Wei-You Zeng, Jian Li, Hongwei Wang, Yu Zhang, Huayi Suo · 2020 · Food and Chemical Toxicology
17. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling–activated Src maintains cholesterol levels and protects from atherosclerosis
    Sangwon Byun, Hyun-Kyung Jung, Jinjing Chen, Young‐Chae Kim, Dong-Hyun Kim, Bo Kong, Grace Liejun Guo, BYRON W. KEMPER, Jongsook Kim Kemper · 2019 · Journal of Biological Chemistry
18. Kaempferol acts on bile acid signaling and gut microbiota to attenuate the tumor burden in ApcMin/+ mice
    Xiaoyan Li, Imran Khan, Guoxin Huang, Yiyan Lu, Liping Wang, Yuanyuan Liu, Linlin Lu, W.L. Wendy Hsiao, Zhongqiu Liu · 2022 · European Journal of Pharmacology
19. Dietary fiber-based regulation of bile salt hydrolase activity in the gut microbiota and its relevance to human disease
    Arthur Kastl, Wenjing Zong, Victoria M. Gershuni, Elliot S. Friedman, Ceylan Tanes, Adoma Boateng, William J. Mitchell, Kathleen O’Connor, Kyle L. Bittinger, Natalie A. Terry et al. · 2022 · Gut Microbes
20. Intestinal barrier function and metabolic/liver diseases
    Siddhartha S. Ghosh, Jing Wang, Paul J. Yannie, Shobha Ghosh · 2020 · Liver Research
21. Inflammation in MASLD progression and cancer
    Yeon Soo Kim, Yunseo Park, Hyunsoo Rho, Tiantian Yao, Bin Gao, Seonghwan Hwang · 2025 · JHEP Reports
22. Role of farnesoid X receptor in cholestasis
    Zhi Qing Yuan, Ke Wei Li · 2016 · Journal of Digestive Diseases
23. Nuclear receptors, cholesterol homeostasis and the immune system
    Shahoei, Sayyed Hamed, Nelson, Erik R. · 2019 · The Journal of Steroid Biochemistry and Molecular Biology
24. Obeticholic acid for the treatment of nonalcoholic steatohepatitis
    Raj A. Shah, Kris V. Kowdley · 2020 · Expert Review of Gastroenterology & Hepatology
25. The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma
    Zhongguang Chen, Lili Jiang, Lifan Liang, Kelly Koral, Qian Zhang, Lei Zhao, Songjian Lu, Junyan Tao · 2021 · American Journal Of Pathology
26. Review of the Relationships Between Human Gut Microbiome, Diet, and Obesity
    Ondřej Patloka, Tomáš Komprda, Gabriela Franke · 2024 · Nutrients
27. Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles
    Boyan Zhang, Folkert Kuipers, Jan Freark de Boer, Jan Albert Kuivenhoven · 2021 · Journal of Clinical Medicine
28. Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Review
    Teresa Da Cunha, Haleh Vaziri, George Y. Wu · 2022 · Journal of Clinical and Translational Hepatology
29. L‐Theanine regulates lipid metabolism by modulating gut microbiota and bile acid metabolism
    Wei Xu, Yingying Kong, Tuo Zhang, Zhihua Gong, Wenjun Xiao · 2022 · Journal of the Science of Food and Agriculture
30. Unequal Effects of Myosin 5B Mutations in Liver and Intestine Determine the Clinical Presentation of Low‐Gamma‐Glutamyltransferase Cholestasis
    Sven C.D. van IJzendoorn, Qinghong Li, Yi‐Ling Qiu, Jian‐She Wang, Arend W. Overeem · 2020 · Hepatology
31. Gut associated metabolites and their roles in Clostridioides difficile pathogenesis
    Andrea Martinez Aguirre, Joseph A. Sorg · 2022 · Gut Microbes
32. Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice
    Shinsmon Jose, Anindita Mukherjee, Olivia Horrigan, Kenneth D.R. Setchell, Wujuan Zhang, Maria E. Moreno‐Fernandez, Heidi M Andersen, Divya Sharma, David B Haslam, Senad Divanovic et al. · 2020 · Mucosal Immunology
33. Ganoderma lucidum polysaccharides improve lipid metabolism against high-fat diet-induced dyslipidemia
    Wenshuai Wang, Yaohan Zhang, Zhiying Wang, Jianjun Zhang, Le Jia · 2023 · Journal of Ethnopharmacology
34. Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis
    Mei Zhou, R. Marc Learned, Stephen J. Rossi, Hui Tian, Alex M. DePaoli, Lei Ling · 2019 · Journal of Lipid Research
35. Current and new pharmacotherapy options for non-alcoholic steatohepatitis
    Yoshio Sumida, Masato Yoneda, Yuji Ogawa, Masashi Yoneda, Takeshi Okanoue, Atsushi Nakajima · 2020 · Expert Opinion on Pharmacotherapy
36. Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes
    Yingjie Wu, An Zhou, Li Tang, Yuanyuan Lei, Bo Tang, Linjing Zhang · 2020 · Journal of Diabetes Research
37. Prebiotic inulin as a treatment of obesity related nonalcoholic fatty liver disease through gut microbiota: a critical review
    Yaolian Hu, Jun He, Ping Zheng, Xiangbing Mao, Zhiqing Huang, Hui Yan, Yuheng Luo, Jie Yu, Junqiu Luo, Bing Yu et al. · 2021 · Critical Reviews in Food Science and Nutrition
38. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and Therapeutic Advances
    Vania Cruz-Ramón, Paulina Chinchilla-López, Oscar Ramírez-Pérez, Nahúm Méndez‐Sánchez · 2017 · Annals of Hepatology
39. MicroRNA‐210 Promotes Bile Acid–Induced Cholestatic Liver Injury by Targeting Mixed‐Lineage Leukemia‐4 Methyltransferase in Mice
    Young‐Chae Kim, Hyun-Kyung Jung, Sunmi Seok, Yang Zhang, Jian Ma, Tiangang Li, BYRON W. KEMPER, Jongsook Kim Kemper · 2019 · Hepatology
40. Targeting bile acid metabolism in obesity reduction: A systematic review and meta‐analysis
    Sik Yu So, Chris Ho Ching Yeung, Catherine Mary Schooling, Hani S El-Nezami · 2020 · Obesity Reviews
41. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis
    Lei Zhang, Zhi‐Gang She, Hongliang Li, Xiao‐Jing Zhang · 2020 · Clinical Science
42. Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions
    Meilin Wei, Wei Tu, Genhua Huang · 2024 · Frontiers in Microbiology
43. Liver ChIP-seq analysis in FGF19-treated mice reveals SHP as a global transcriptional partner of SREBP-2
    Young‐Chae Kim, Sangwon Byun, Yang Zhang, Sunmi Seok, BYRON W. KEMPER, Jian Ma, Jongsook Kim Kemper · 2015 · Genome biology
44. Linderae Radix Ethanol Extract Alleviates Diet-Induced Hyperlipidemia by Regulating Bile Acid Metabolism Through gut Microbiota
    Tao Jiang, XU Chu-yun, Huifang Liu, Muyi Liu, Minmin Wang, Jiarui Jiang, Guangji Zhang, Chuqi Yang, Jianbo Huang, Zhaohuan Lou · 2021 · Frontiers in Pharmacology
45. The FXR-FGF19 Gut–Liver Axis as a Novel “Hepatostat”
    Matias Antonio Avila, Antonio Moschetta · 2015 · Gastroenterology
46. Short bowel syndrome results in increased gene expression associated with proliferation, inflammation, bile acid synthesis and immune system activation: RNA sequencing a zebrafish SBS model
    Kathy A. Schall, Matthew Edward Thornton, Mubina A. Isani, Kathleen A. Holoyda, Xiaogang Hou, Ching‐Ling Lien, Brendan H. Grubbs, Tracy C. Grikscheit · 2017 · BMC Genomics
47. Exposure to high fructose corn syrup during adolescence in the mouse alters hepatic metabolism and the microbiome in a sex‐specific manner
    Shazia Bhat, Sara Elizabeth Pinney, Katherine M. Kennedy, Cole R. McCourt, Miles A. Mundy, Michael Gordon Surette, Deborah Magdalena Sloboda, Rebecca Anne Simmons · 2021 · The Journal of Physiology
48. MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases
    David Peick Sonne · 2021 · European Journal of Endocrinology
49. The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE−/−FXR−/− Mice
    Yenna Lee, Bo-Rahm Kim, Geun-Hyung Kang, Gwan Jae Lee, Young Joo Park, Haeryoung Kim, Hak Chul Jang, Sung Hee Choi · 2021 · Endocrinology and Metabolism
50. Defective FXR-SHP Regulation in Obesity Aberrantly Increases miR-802 Expression, Promoting Insulin Resistance and Fatty Liver
    Sunmi Seok, Hao Sun, Young‐Chae Kim, BYRON W. KEMPER, Jongsook Kim Kemper · 2020 · Diabetes
51. Xyloglucan affects gut-liver circulating bile acid metabolism to improve liver damage in mice fed with high-fat diet
    Jinhua Cheng, Xiujuan Jiang, Jingwen Li, Shanshan Zhou, Tingmei Bai, Wen Qin, Hua Li, Yuheng Luo, Zhiqing Huang, Yuntao Liu et al. · 2019 · Journal of Functional Foods
52. Identifying a Novel Bile Salt Hydrolase from the Keystone Gut Bacterium Christensenella minuta
    Guillaume Déjean, Héloïse Tudela, Lisa Bruno, Déborah Kissi, Georges Rawadi, Sandrine P. Claus · 2021 · Microorganisms
53. Fecal microbiome and bile acid metabolome in adult short bowel syndrome
    Boutte, Harold J., Chen, Jacqueline, Wylie, Todd N., Wylie, Kristine M., Xie, Yan, Geisman, Mackenzie, Prabu, Anirudh, Gazit, Vered, Tarr, Phillip I., Levin, Marc S. et al. · 2022 · American Journal of Physiology-Gastrointestinal and Liver Physiology
54. Effects of Acute and Chronic Resistance Exercise on the Skeletal Muscle Metabolome
    Sebastian Gehlert, Patrick Weinisch, Werner Römisch‐Margl, Richard T. Jaspers, Anna Artati, Jerzy Adamski, Kenneth Allen Dyar, Thorben Aussieker, Daniel Jacko, Wilhelm Bloch et al. · 2022 · Metabolites
55. Approaches to discern if microbiome associations reflect causation in metabolic and immune disorders
    Marijana Basic, Dominique P. Dardevet, Peter Michael Abuja, Silvia Bolsega, Stéphanie Bornes, Robert Caesar, Francesco Maria Calabrese, Massimo Collino, Maria De Angelis, Philippe Gérard et al. · 2022 · Gut Microbes
56. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination
    Hyun-Kyung Jung, Jinjing Chen, Xiangming Hu, Hao Sun, Shwu-Yuan Wu, Cheng‐Ming Chiang, BYRON W. KEMPER, Lin‐Feng Chen, Jongsook Kim Kemper · 2020 · JCI Insight
57. Drug Screening, Oral Bioavailability and Regulatory Aspects: A Need for Human Organoids
    Tamara Zietek, Wolfgang Boomgaarden, Eva Rath · 2021 · Pharmaceutics
58. Pregnane X receptor (PXR) deficiency improves high fat diet-induced obesity via induction of fibroblast growth factor 15 (FGF15) expression
    Liyang Zhao, Jiayi Xu, Zhe Shi, Neal A. Englert, Shuyun Zhang · 2017 · Biochemical Pharmacology
59. Glucose‐lowering effects and mechanisms of the bile acid‐sequestering resin sevelamer
    Andreas Brønden, Stine Ulrik Mikkelsen, David Peick Sonne, Morten Hansen, Christoffer Søvsø Våben, Maria N. Gabe, METTE MARIE ROSENKILDE, Valentina Tremaroli, Hao Wu, Fredrik Bäckhed et al. · 2018 · Diabetes Obesity and Metabolism
60. Pleiotropic roles of FXR in liver and colorectal cancers
    Xiongfei Huang, Mingjie Fan, Wendong Huang · 2022 · Molecular and Cellular Endocrinology
61. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications
    Mariana Michelle Ramírez-Mejía, Guadalupe Ponciano‐Rodríguez, Mohammed Eslam, Nahúm Méndez-Sánchez · 2025 · Therapeutic Advances in Endocrinology and Metabolism
62. Diammonium Glycyrrhizinate Ameliorates Obesity Through Modulation of Gut Microbiota-Conjugated BAs-FXR Signaling
    Yun Li, Huiqin Hou, Xianglu Wang, Xin Dai, Wanru Zhang, Qiang Tang, Yue Dong, Chen Yan, Bangmao Wang, Zhengxiang Li et al. · 2021 · Frontiers in Pharmacology
63. Effects of supplemented isoenergetic diets varying in cereal fiber and protein content on the bile acid metabolic signature and relation to insulin resistance
    Weickert, Martin O., Hattersley, John G., Kyrou, Ioannis, Arafat, Ayman M., Rudovich, Natalia, Roden, Michael, Nowotny, Peter, von Loeffelholz, Christian, Matysik, Silke, Schmitz, Gerd et al. · 2018 · Nutrition & Diabetes
64. Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease
    Qiang Ren, Ya Chen, Zongtao Zhou, Zongyu Cai, Shixuan Jiao, Wanqiu Huang, Bin Wang, Siliang Chen, Wenxin Wang, Zhijun Cao et al. · 2023 · Journal of Medicinal Chemistry
65. Bifidobacterium animalis subsp. lactis F1–7 Alleviates Lipid Accumulation in Atherosclerotic Mice via Modulating Bile Acid Metabolites to Downregulate Intestinal FXR
    Xi Liang, Xiumei Zheng, Peng Wang, Huaqi Zhang, Yiqing Ma, Hui Liang, Zhe Zhang · 2024 · Journal of Agricultural and Food Chemistry
66. New Therapeutic Targets in Autoimmune Cholangiopathies
    Alessio Gerussi, Martina De Luca, Laura Cristoferi, Vincenzo Ronca, Clara Mancuso, Chiara Milani, Daphne D’Amato, Sarah Elizabeth O'Donnell, Marco Carbone, Pietro Invernizzi · 2020 · Frontiers in Medicine
67. Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β‐defensin‐1 and ‐2 secretion by colonic epithelial cells
    Natalia Lajczak, Vinciane Saint‐Criq, Aoife M. O’Dwyer, Alessia Perino, Luciano Adorini, Kristina Schoonjans, Stephen J. Keely · 2017 · The FASEB Journal
68. Intestinal FGF15 regulates bile acid and cholesterol metabolism but not glucose and energy balance
    Nadejda Bozadjieva-Kramer, Jae Hoon Shin, Ziru Li, Alan C. Rupp, Nicole Miller, Stace Kernodle, Nicolas Lanthier, Paulina Henry, Nikhil Seshadri, Andriy Myronovych et al. · 2024 · JCI Insight
69. Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases
    Carmen Festa, Simona De Marino, Adriana Carino, Valentina Sepe, Silvia Marchianò, Sabrina Cipriani, Francesco Saverio Di Leva, Vittorio Limongelli, Maria C. Monti, Angela Capolupo et al. · 2017 · Frontiers in Pharmacology
70. Gall bladder: The metabolic orchestrator
    Qi Li, Yu Tian, Yongsheng Chen · 2019 · Diabetes/Metabolism Research and Reviews
71. Gaussian graphical modeling of the serum exposome and metabolome reveals interactions between environmental chemicals and endogenous metabolites
    Vincent Bessonneau, Roy R. L. Gerona, Jessica Trowbridge, Rachel G. Grashow, Thomas S. Lin, Heather Buren, Rachel A. Morello-Frosch, Ruthann A. Rudel · 2021 · Scientific Reports
72. The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
    Marta Mazzetti, Giulia Marconi, Martina Mancinelli, A. Benedetti, Marco Marzioni, Luca Maroni · 2021 · Journal of Clinical Medicine
73. Regulation of Hepatic Glucose Metabolism by FoxO Proteins, an Integrated Approach
    Terry G. Unterman · 2017 · Current topics in developmental biology/Current Topics in Developmental Biology
74. Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid
    Maria C. van Hooff, E. Werner, A.J. van der Meer · 2024 · European Journal of Internal Medicine
75. Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer
    Yiming Yin, Mengge Wang, Wenjie Gu, Lili Chen · 2021 · Biochemical Pharmacology
76. The bile–gut axis and metabolic consequences of cholecystectomy
    Andreas H. Lange, Miriam G Pedersen, Anne‐Marie Ellegaard, Henriette Holst Nerild, Andreas Brønden, David Peick Sonne, Filip Krag Knop · 2024 · European Journal of Endocrinology
77. Hepatic Autophagy Deficiency Remodels Gut Microbiota for Adaptive Protection via FGF15-FGFR4 Signaling
    Shengmin Yan, Bilon Khambu, Xiaoyun Chen, Zheng Dong, Grace Liejun Guo, Xiao‐Ming Yin · 2020 · Cellular and Molecular Gastroenterology and Hepatology
78. Hepatic metabolic regulation by nuclear factor E4BP4
    Zifeng Zhao, Lei Yin, Feihua Wu, Xin Tong · 2020 · Journal of Molecular Endocrinology
79. Cyp2c-deficiency depletes muricholic acids and protects against high-fat diet-induced obesity in male mice but promotes liver damage
    Antwi‐Boasiako Oteng, Sei Higuchi, Alexander S. Banks, Rebecca A. Haeusler · 2021 · Molecular Metabolism
80. Preventive Effects of l -Glutamine on High-Fat Diet-Induced Metabolic Disorders Linking with Regulation of Intestinal Barrier Integrity, Hepatic Lipid Metabolism, and Gut Microbiota in Rats
    Yu He, Zhuan Song, Yun Seong Ji, Patrick Tso, Zhenlong Wu · 2022 · Journal of Agricultural and Food Chemistry
81. Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
    Yingkun Sheng, Guibing Meng, Min Zhang, Xiaopeng Chen, Xin Chai, Haiyang Yu, Lifeng Han, Qilong Wang, Yuefei Wang, Miaomiao Jiang · 2024 · Journal of Ethnopharmacology
82. Farnesoid X receptor and fibroblast growth factor 15/19 as pharmacological targets
    Syeda Maliha, Grace Liejun Guo · 2021 · Liver Research
83. Enterobacter aerogenes ZDY01 inhibits choline-induced atherosclerosis through CDCA-FXR-FGF15 axis
    Jinghui Tang, Manman Qin, Le Min Tang, Dan Shan, Cheng Zhang, Yifeng Zhang, Hua Wei, Liang Qiu, Jun Yu · 2021 · Food & Function
84. Regulation of Liver Energy Balance by the Nuclear Receptors Farnesoid X Receptor and Peroxisome Proliferator Activated Receptor α
    Kang Ho Kim, David D. Moore · 2017 · Digestive Diseases
85. Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
    Grazia Pennisi, Ciro Celsa, Federica Spatola, Marcello Dallio, Alessandro Federico, Salvatore Petta · 2019 · International Journal of Environmental Research and Public Health
86. Targeting Gut Microbiota for the Treatment of Primary Biliary Cholangitis: From Bench to Bedside
    Li Zhang, Ling Yang, Huikuan Chu · 2023 · Journal of Clinical and Translational Hepatology
87. Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention
    Giovanna Gallo, Gabriele Nalli, Francesco Baratta, Giovambattista Desideri, Carmine Savoia · 2025 · International Journal of Molecular Sciences
88. Cholecystectomy as a risk factor for non-alcoholic fatty liver disease development
    Itzayana Rodríguez‐Antonio, Guillermo Nahúm López-Sánchez, Victor Y. Garrido-Camacho, Misael Uribe, Norberto Carlos Chávez-Tapia, Natalia Nuño‐Lámbarri · 2020 · HPB
89. Farnesoid X receptor: An important factor in blood glucose regulation
    Yangfeng Hou, Wenjing Fan, Wenling Yang, Abdul Qadir Samdani, Ampadu O. Jackson, Shun-Lin Qu · 2019 · Clinica Chimica Acta
90. A Possible Mechanism of Metformin in Improving Insulin Resistance in Diabetic Rat Models
    Mengsiyu Li, Xiaowen Hu, Yeqiu Xu, Xiaolin Hu, Chunxue Zhang, Shuguang Pang · 2019 · International Journal of Endocrinology
91. Intestinal Inflammation Alters the Expression of Hepatic Bile Acid Receptors Causing Liver Impairment
    Anna Negroni, Noemi Fiaschini, Francesca Palone, Roberta Vitali, Eleonora Colantoni, Ilaria Laudadio, Salvatore Oliva, Marina Aloi, Salvatore Cucchiara, Laura Stronati · 2020 · Journal of Pediatric Gastroenterology and Nutrition
92. The dichotomous roles of microbial-modified bile acids 7-oxo-DCA and isoDCA in intestinal tumorigenesis
    Xingchen Dong, Fei Sun, Henry Secaira-Morocho, Alisa Hui, Ke Wang, Chunmiao Cai, Shirsa Udgata, Brian Low, Songlin Wei, Xinyi Chen et al. · 2024 · Proceedings of the National Academy of Sciences
93. Microbiome−mediated crosstalk between T2DM and MASLD: a translational review focused on function
    Jing, Menghui, Jiang, Yuanye · 2025 · Frontiers in Endocrinology
94. Cholesterol-Lowering Drugs
    E.L. Albuquerque, Umberto Laino Fulco, E. W. S. Caetano, V. N. Freire · 2020 · Cambridge University Press eBooks
95. Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: an integrative perspective from molecular pathways to clinical challenges
    Jingyuan Ma, Yanfen Ma, Xing Wan, Junchen Li, Yunshu Zhang, Jifeng Liu, Yunhai Gao · 2025 · Frontiers in Endocrinology
96. Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology
    Andreas Brønden, Filip Krag Knop · 2019 · The Journal of Clinical Endocrinology & Metabolism
97. An insight into the mechanism and molecular basis of dysfunctional immune response involved in cholestasis
    Mengzhi Zou, Aizhen Wang, Jiajie Wei, Heng Cai, Zixun Yu, Luyong Zhang, Xinzhi Wang · 2021 · International Immunopharmacology
98. Feeding activates FGF15‐SHP‐TFEB‐mediated lipophagy in the gut
    Sunmi Seok, Young‐Chae Kim, Yang Zhang, Bo Kong, Grace Liejun Guo, Jian Ma, BYRON W. KEMPER, Jongsook Kim Kemper · 2022 · The EMBO Journal
99. Exploring the Structural and Functional Diversity among FGF Signals: A Comparative Study of Human, Mouse, and Xenopus FGF Ligands in Embryonic Development and Cancer Pathogenesis
    Ravi Shankar Goutam, Vijay Kumar, Unjoo Lee, Jaebong Kim · 2023 · International Journal of Molecular Sciences
100. Yinchen decoction protects against cholic acid diet-induced cholestatic liver injury in mice through liver and ileal FXR signaling
     Guochao Song, Bin Zou, Jing Zhao, Fengyi Weng, Yue Li, Xiaoqing Xu, Shuang Zhang, Dongming Yan, Jingyi Jin, Xin Sun et al. · 2023 · Journal of Ethnopharmacology